Stocks News

LAST PRICE
125.8850
TODAY'S CHANGE (%)
Trending Down-4.5250 (-3.4698%)

Bid / Lots
125.8300/ 4
Ask / Lots
126.2500/ 4
Open / Previous Close
130.7700 / 130.4100
Day Range
Low 125.8700
High 131.9700
52 Week Range
Low 83.7500
High 161.0000
Volume
58,191
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

May 22, 2024
- European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading, from 11:01AM ET on Wednesday May 22, 2024 by MT Newswires
  11:01AM ET on Wednesday May 22, 2024 by MT Newswires
  Companies Mentioned: FMS, GSK, TRIB, SQNS, GRFS, TRVG, VRNA, GNFT, MREO, BCYC, BNTX, BHP, SLN, EVAX, ASND, BDRX
  11:01 AM EDT, 05/22/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts fell Wednesday morning, declining 0.48% to 1,423.09 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by bi...
May 16, 2024
- --Morgan Stanley Adjusts Ascendis Pharma Price Target to $140 From $116, Maintains Equal Weight Rating, from 12:17PM ET on Thursday May 16, 2024 by MT Newswires
  12:17PM ET on Thursday May 16, 2024 by MT Newswires
  Companies Mentioned: ASND
  12:17 PM EDT, 05/16/2024 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contac...
- DJ Ascendis Pharma Is Maintained at Equal-Weight by Morgan Stanley, from 12:11PM ET on Thursday May 16, 2024 by Dow Jones
  12:11PM ET on Thursday May 16, 2024 by Dow Jones
  Companies Mentioned: ASND
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/ASND/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 16, 2024 12:11 ET (16:11 GMT)
May 15, 2024
- DJ Ascendis Pharma Price Target Maintained With a $173.00/Share by Cantor Fitzgerald, from 8:37AM ET on Wednesday May 15, 2024 by Dow Jones
  8:37AM ET on Wednesday May 15, 2024 by Dow Jones
  Companies Mentioned: ASND
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/ASND/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 15, 2024 08:37 ET (12:37 GMT)
May 14, 2024
- US Equity Markets Close Higher Tuesday as Producer Prices Rise, from 4:07PM ET on Tuesday May 14, 2024 by MT Newswires
  4:07PM ET on Tuesday May 14, 2024 by MT Newswires
  Companies Mentioned: AMC, ASND
  04:07 PM EDT, 05/14/2024 (MT Newswires) -- US equity markets ended higher Tuesday as the producer price index increased more than expected. * The US Producer Price Index rose 0.5% in April following a downwardly revised 0.1% decrease in March, above...

Today
- INVESTIGATION ACTION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 1 hour ago by Accesswire
  1 hour ago by Accesswire
  Companies Mentioned: BPMC
- CEREVEL THERAPEUTICS ALERT: Cerevel's $45 Merger Offer From AbbVie is Under Investigation (Nasdaq: CERE) - Contact BFA Law to Discuss How this Impacts You, from 6 hours ago by GlobeNewswire
  6 hours ago by GlobeNewswire
  Companies Mentioned: CERE
Yesterday
- IMPORTANT STOCKHOLDER ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 14 hours ago by Accesswire
  14 hours ago by Accesswire
  Companies Mentioned: BPMC
May 26, 2024
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Blueprint Medicines Corporation and Encourages Investors to Contact the Firm, from 8:12PM ET on Sunday May 26, 2024 by GlobeNewswire
  8:12PM ET on Sunday May 26, 2024 by GlobeNewswire
  Companies Mentioned: BPMC
May 25, 2024
- CERE (NASDAQ) ALERT: Cerevel's $45 Merger Offer From AbbVie is Under Investigation; Contact BFA Law to Discuss Your Rights, from 5:18AM ET on Saturday May 25, 2024 by GlobeNewswire
  5:18AM ET on Saturday May 25, 2024 by GlobeNewswire
  Companies Mentioned: CERE
May 24, 2024
- HC Wainwright Adjusts Legend Biotech Price Target to $73 From $86, Maintains Buy Rating, from 8:11AM ET on Friday May 24, 2024 by MT Newswires
  8:11AM ET on Friday May 24, 2024 by MT Newswires
  Companies Mentioned: LEGN
- Cerevel's Merger with AbbVie for $45 Per Share Leads to Investigation - Contact BFA Law to Discuss How this Impacts You, from 7:39AM ET on Friday May 24, 2024 by Accesswire
  7:39AM ET on Friday May 24, 2024 by Accesswire
  Companies Mentioned: CERE
- Deutsche Bank Starts Legend Biotech With Buy Rating, from 7:11AM ET on Friday May 24, 2024 by MT Newswires
  7:11AM ET on Friday May 24, 2024 by MT Newswires
  Companies Mentioned: LEGN
May 23, 2024
- Blueprint Medicines Says BLU-222 Combination Well Tolerated for Inhibitor in Type of Breast Cancer, from 5:38PM ET on Thursday May 23, 2024 by MT Newswires
  5:38PM ET on Thursday May 23, 2024 by MT Newswires
  Companies Mentioned: BPMC
- Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting, from 5:05PM ET on Thursday May 23, 2024 by PR Newswire
  5:05PM ET on Thursday May 23, 2024 by PR Newswire
  Companies Mentioned: BPMC

Ascendis Pharma A/S
NASDAQ:ASNDUnited States

Search Criteria

May 22, 2024

European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading, from 11:01AM ET on Wednesday May 22, 2024 by MT Newswires

May 16, 2024

--Morgan Stanley Adjusts Ascendis Pharma Price Target to $140 From $116, Maintains Equal Weight Rating, from 12:17PM ET on Thursday May 16, 2024 by MT Newswires

DJ Ascendis Pharma Is Maintained at Equal-Weight by Morgan Stanley, from 12:11PM ET on Thursday May 16, 2024 by Dow Jones

May 15, 2024

DJ Ascendis Pharma Price Target Maintained With a $173.00/Share by Cantor Fitzgerald, from 8:37AM ET on Wednesday May 15, 2024 by Dow Jones

May 14, 2024

US Equity Markets Close Higher Tuesday as Producer Prices Rise, from 4:07PM ET on Tuesday May 14, 2024 by MT Newswires

Peers Headlines

Today

INVESTIGATION ACTION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 1 hour ago by Accesswire

CEREVEL THERAPEUTICS ALERT: Cerevel's $45 Merger Offer From AbbVie is Under Investigation (Nasdaq: CERE) - Contact BFA Law to Discuss How this Impacts You, from 6 hours ago by GlobeNewswire

Yesterday

IMPORTANT STOCKHOLDER ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 14 hours ago by Accesswire

May 26, 2024

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Blueprint Medicines Corporation and Encourages Investors to Contact the Firm, from 8:12PM ET on Sunday May 26, 2024 by GlobeNewswire

May 25, 2024

CERE (NASDAQ) ALERT: Cerevel's $45 Merger Offer From AbbVie is Under Investigation; Contact BFA Law to Discuss Your Rights, from 5:18AM ET on Saturday May 25, 2024 by GlobeNewswire

May 24, 2024

HC Wainwright Adjusts Legend Biotech Price Target to $73 From $86, Maintains Buy Rating, from 8:11AM ET on Friday May 24, 2024 by MT Newswires

Cerevel's Merger with AbbVie for $45 Per Share Leads to Investigation - Contact BFA Law to Discuss How this Impacts You, from 7:39AM ET on Friday May 24, 2024 by Accesswire

Deutsche Bank Starts Legend Biotech With Buy Rating, from 7:11AM ET on Friday May 24, 2024 by MT Newswires

May 23, 2024

Blueprint Medicines Says BLU-222 Combination Well Tolerated for Inhibitor in Type of Breast Cancer, from 5:38PM ET on Thursday May 23, 2024 by MT Newswires

Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting, from 5:05PM ET on Thursday May 23, 2024 by PR Newswire